Scholars Central

Research articlePublished 20 Aug 2011

Road Map to Drug Discovery and Development–Inhibiting C-reactive protein for the Treatment of Cardiovascular Disease

Authors: Jan Torzewski, Kefei Li, Oliver Zimmermann

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Elevated plasma levels of high sensitivity C-reactive protein (hs-CRP), the prototype acute phase protein, are predictive for future cardiovascular events. Inclusion of information on hs-CRP values in patients with other cardiovascular risk factors assist physicians in medical decision making. Evidence also suggests that CRP plays a direct role in cardiovascular disease by activating the complement system and interacting with macrophages via Fcγ receptors. Thus, specific CRP inhibition may be a novel approach for reducing cardiovascular mortality. Here, we discuss the road map to the development of CRP inhibitors. As the topic is scientifically very controversial, the road map to drug development is severely influenced by diverse scientific views and also patent law considerations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectCardiology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jan Torzewski”
  • BylineArticles whose byline prints “Kefei Li”
  • BylineArticles whose byline prints “Oliver Zimmermann”